GlassScriptPhysician profile
Ahsen Ali Butt
NPI 1528001633
$5,131.07
in general payments reported to CMS, 2019-2025
34 companies · $895 in 2025
The $895 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $757 · 2021: $1,032 · 2022: $365 · 2023: $752 · 2024: $938 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $647.12 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $611.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $491.64 | 2020-2024 | |
| Abbvie INC. | $470.10 | 2020-2025 | Qulipta, Linzess, Viberzi |
| Lilly USA, LLC | $394.15 | 2019-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.61 | 2019-2025 | Jardiance |
| Pfizer INC. | $291.15 | 2019-2025 | |
| Grifols USA, LLC | $188.59 | 2022-2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $173.95 | 2021-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $147.70 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $139.16 | 2023-2025 | Dexcom G6 Transmitter |
| Redhill Biopharma INC. | $115.93 | 2020-2021 | |
| Daiichi Sankyo INC. | $111.10 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $104.03 | 2019-2021 | |
| Abbott Laboratories | $86.33 | 2024-2025 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $82.43 | 2025 | |
| Boston Scientific Corporation | $65.62 | 2023-2024 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $63.28 | 2023-2024 | |
| Amgen INC. | $60.33 | 2019-2024 | Repatha, Otezla, Evenity |
| Sunovion Pharmaceuticals INC. | $59.12 | 2021 | |
| Amarin Pharma, INC. | $50.67 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $50.62 | 2019-2020 | |
| Nevro Corp. | $46.88 | 2021 | |
| Xeris Pharmaceuticals, INC. | $43.84 | 2023 | Gvoke Hypopen |
| Indivior INC. | $40.56 | 2020 | |
| Corcept Therapeutics | $34.58 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $28.70 | 2023 | |
| Supernus Pharmaceuticals, INC. | $24.57 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.35 | 2024 | Crysvita |
| Esperion Therapeutics, INC. | $23.14 | 2021 | |
| Exact Sciences Corporation | $21.95 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $20.15 | 2025 | Auvelity |
| Ardelyx, INC. | $16.33 | 2024 | Ibsrela |
| Bardy Diagnostics, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahsen Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.